TrialAnnals of hematology2022

Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.

Yu-Wen Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.